Menu Get Started
Cart
Name Price QTY

Subtotal:
Taxes and shipping calculated at checkout

View cart

Your cart is empty
/ Anti-Inflammatory Corticosteroid / Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications

All Articles

Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications

Updated Wed, Apr 02, 2025

Overview:
This comprehensive review explores the mechanisms, pharmacokinetics, and safety profiles of intranasal corticosteroids (INSs), which are widely used to treat allergic rhinitis, rhinosinusitis, and nasal polyposis. The paper highlights the development of newer corticosteroid molecules that provide potent local anti-inflammatory effects with minimal systemic absorption.

The Takeaways:

  • INSs are highly effective in managing nasal inflammatory conditions by acting directly on the nasal mucosa to reduce immune activity with minimal systemic effects.

  • Newer corticosteroids have superior potency and low systemic bioavailability due to their high lipophilicity and optimized molecular structure.

  • Systemic absorption is negligible with these agents, especially compared to older corticosteroids like triamcinolone and beclomethasone, which have higher systemic bioavailability (34–49%).

  • Long-term studies show no adverse effects on growth or HPA axis function in children, affirming the safety of modern INSs even with prolonged use.

Why It Matters:
Intranasal corticosteroids remain the cornerstone of treatment for moderate to severe allergic rhinitis due to their high efficacy and excellent safety profile. Advances in drug design have created molecules that are powerful at the site of inflammation but rarely enter the bloodstream, lowering the risk of systemic side effects. These characteristics make them suitable for daily, long-term use in both adults and children.

The Link to Allermi:
Allermi incorporates modern, evidence-backed corticosteroids into its custom nasal spray formulas. These agents provide high local potency with low systemic exposure, aligning with the safety and efficacy benchmarks outlined in this review. This study reinforces Allermi’s science-first approach: selecting corticosteroids that deliver strong inflammation control without compromising long-term patient safety.

For more details, refer to the full study: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications